Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389:589–601. https://doi.org/10.1056/NEJMoa2304194

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF (2023) Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 29:615–622. https://doi.org/10.1038/s41591-022-02141-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY (2021) Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res 27:4491–4499. https://doi.org/10.1158/1078-0432.Ccr-21-0611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165. https://doi.org/10.1002/1097-0142(19881115)62:10%3C2152::aid-cncr2820621015%3E3.0.co;2-t

Article  CAS  PubMed  Google Scholar 

van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120:297–304. https://doi.org/10.1007/s00401-010-0725-7

Article  PubMed  PubMed Central  Google Scholar 

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M (2017) Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG oncology RTOG 9813. Neuro Oncol 19:252–258. https://doi.org/10.1093/neuonc/now236

Article  CAS  PubMed  Google Scholar 

Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A (2020) Comprehensive genomic analysis in NRG oncology/rtog 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38:3407–3417. https://doi.org/10.1200/jco.19.02983

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duregon E, Bertero L, Pittaro A, Soffietti R, Rudà R, Trevisan M, Papotti M, Ventura L, Senetta R, Cassoni P (2016) Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget 7:21190–21198. https://doi.org/10.18632/oncotarget.8498

Article  PubMed  PubMed Central  Google Scholar 

Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129:585–596. https://doi.org/10.1007/s00401-015-1398-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132

Article  CAS  PubMed  Google Scholar 

Dao Trong P, Gluszak M, Reuss D, von Deimling A, Wick A, König L, Debus J, Herold-Mende C, Unterberg A, Jungk C (2023) Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort. J Neurooncol 161:605–615. https://doi.org/10.1007/s11060-022-04230-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent A, van den Bent MJ (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20:103–112. https://doi.org/10.1093/neuonc/nox176

Article  CAS  PubMed  Google Scholar 

Park YW, Park KS, Park JE, Ahn SS, Park I, Kim HS, Chang JH, Lee SK, Kim SH (2023) Qualitative and quantitative magnetic resonance imaging phenotypes may predict CDKN2A/B homozygous deletion status in isocitrate dehydrogenase-mutant astrocytomas: a multicenter study. Korean J Radiol 24:133–144. https://doi.org/10.3348/kjr.2022.0732

Article  PubMed  PubMed Central  Google Scholar 

Katzendobler S, Niedermeyer S, Blobner J, Trumm C, Harter PN, von Baumgarten L, Stoecklein VM, Tonn JC, Weller M, Thon N, Weller J (2024) Determinants of long-term survival in patients with IDH-mutant gliomas. J Neurooncol 170:655–664. https://doi.org/10.1007/s11060-024-04826-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weller J, Katzendobler S, Blobner J, Thiele F, Becker H, Quach S, Egensperger R, Niyazi M, Suchorska B, Thon N, Weller M, Tonn JC (2022) Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3. J Neurooncol 160:149–158. https://doi.org/10.1007/s11060-022-04128-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA (2021) Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol 23:1872–1884. https://doi.org/10.1093/neuonc/noab081

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joyner DA, Garrett J, Batchala PP, Rama B, Ravicz JR, Patrie JT, Lopes MB, Fadul CE, Schiff D, Jain R, Patel SH (2023) MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. Neuroradiology 65:121–129. https://doi.org/10.1007/s00234-022-03038-0

Article  PubMed  Google Scholar 

Suchorska B, Schüller U, Biczok A, Lenski M, Albert NL, Giese A, Kreth FW, Ertl-Wagner B, Tonn JC, Ingrisch M (2019) Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. Eur J Cancer 107:15–27. https://doi.org/10.1016/j.ejca.2018.10.019

Article  CAS  PubMed  Google Scholar 

Reis J, Stahl R, Zimmermann H, Ruf V, Thon N, Kunz M, Liebig T, Forbrig R (2021) Advanced MRI findings in medulloblastomas: relationship to genetic subtypes, histopathology, and immunohistochemistry. J Neuroimaging 31:306–316. https://doi.org/10.1111/jon.12831

Article  PubMed  Google Scholar 

Wollring MM, Werner JM, Ceccon G, Lohmann P, Filss CP, Fink GR, Langen KJ, Galldiks N (2023) Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas. J Neurooncol 162:481–488. https://doi.org/10.1007/s11060-022-04218-x

Article  PubMed  Google Scholar 

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084. https://doi.org/10.1200/jco.2002.08.121

Article  PubMed  Google Scholar 

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35:2439–2449. https://doi.org/10.1200/jco.2017.72.7511

Article  CAS  PubMed  PubMed Central  Google Scholar 

Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385. https://doi.org/10.1002/ijc.20575

Article  CAS  PubMed  Google Scholar 

van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F,